Kurzfassung

A phase 3, multicenter, randomized, open-label, active-controlled study to assess the efficacy and safety of Maribavir treatment compared to investigator-assigned treatment in transplant recipients with Cytomegalovirus (CMV) infections that are refractory or resistant to treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir